BIO WEBINAR SK Bioscience comes up with 2-track strategy to become global vaccine powerhouse
Lee Sang-mok, head of Strategic Planning Division of SK Bioscience, speaks during The Korea Times' Bio Webinar, March 26. Captured during the eventBy Baek Byung-yeulLogo for SK BioscienceSK Bioscience has set its sights on becoming the global vaccine powerhouse by developing its own COVID-19 vaccine and expanding its contract development and manufacturing organization (CDMO) business, said Lee Sang-mok, head of the company's Strategic Planning Division, March 26.“SK Bioscience is implementing a two-track strategy ― developing our own vaccines and manufacturing and distributing vaccines developed by global vaccine makers. Based on our capabilities in every process in vaccine business, we are aiming to become a vaccine specialist company,” Lee said during The Korea Times' Bio Webinar. The Korea Times hosted the online seminar to shed light on the government's steps to attract global biotech entities for its plan to build a cluster here, and discuss diverse issues regarding the biotech industry.Park Jae-young, director general of the Manufacturing Industry Department at the
